Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Curr Opin Oncol. 2023 Jul 1;35(4):301-308. doi: 10.1097/CCO.0000000000000954. Epub 2023 May 9.
Retroperitoneal soft-tissue sarcomas (RPS) are a group of rare, histologically distinct tumours with variable recurrence patterns depending on histological type. This review will discuss the growing body of evidence supporting histology-specific, multidisciplinary management and highlight areas of future research for patients with RPS.
Histology-tailored surgery is the cornerstone of management in patients with localized RPS. Further efforts to develop resectability criteria and identify patients who will benefit from neoadjuvant treatment strategies will help standardize the treatment of patients with localized RPS. Surgery for local recurrence is well tolerated in selected patients and re-iterative surgery in liposarcoma (LPS) may be beneficial at the time of local recurrence. The management of advanced RPS holds promise with several trials currently investigating systemic treatment beyond conventional chemotherapy.
The management of RPS has made significant progress over the past decade owing to international collaboration. Ongoing efforts to identify patients who will derive the most benefit from all treatment strategies will continue to advance the field of RPS.
腹膜后软组织肉瘤(RPS)是一组罕见的、具有不同组织学类型的、具有不同复发模式的、具有明确组织学特征的肿瘤。本文将讨论支持针对特定组织学的多学科管理的不断增加的证据,并强调 RPS 患者未来研究的领域。
针对局限性 RPS 患者,基于组织学的手术是管理的基石。进一步努力制定可切除性标准,并确定哪些患者将受益于新辅助治疗策略,将有助于为局限性 RPS 患者的治疗标准化。在选择的患者中,局部复发性疾病的手术耐受性良好,在局部复发时,脂肪肉瘤(LPS)的再次手术可能有益。由于目前正在研究超出传统化疗的系统治疗,晚期 RPS 的治疗具有很大的希望。
由于国际合作,过去十年中 RPS 的治疗取得了重大进展。为了继续推进 RPS 领域的发展,正在努力确定哪些患者将从所有治疗策略中获益最多。